JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$4.65B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.08B |
| 3 |
Microsoft
MSFT
|
+$2.05B |
| 4 |
Vanguard Total International Bond ETF
BNDX
|
+$1.64B |
| 5 |
Micron Technology
MU
|
+$1.39B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMJ
JP Morgan Alerian MLP Index ETN 5/24/24
AMJ
|
+$2.4B |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.11B |
| 3 |
Progressive
PGR
|
+$1.64B |
| 4 |
Salesforce
CRM
|
+$1.54B |
| 5 |
Adobe
ADBE
|
+$1.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 24.15% |
| 2 | Technology | 24.03% |
| 3 | Healthcare | 9.24% |
| 4 | Consumer Discretionary | 8.79% |
| 5 | Financials | 8.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3201
PUT
Baxter International
BAX
$12.1B
| $3.46M | ﹤0.01% |
103,300
-3,400
| -3% | -$125K |
2022 Q4
6 quarters
|
|
|
EXK
3202
Endeavour Silver
EXK
$2.55B
| $3.45M | ﹤0.01% |
980,372
+978,572
| +54,365% | +$3.18M |
2023 Q4
2 quarters
|
|
|
XYZ
3203
PUT
Block Inc
XYZ
$44.7B
| $3.45M | ﹤0.01% |
53,500
-105,700
| -66% | -$7.39M |
2019 Q1
21 quarters
|
|
3204
CALL
Abbott
ABT
$169B
| $3.45M | ﹤0.01% |
33,200
+2,100
| +7% | +$223K |
2023 Q4
2 quarters
|
|
3205
VanEck Emerging Markets High Yield Bond ETF
HYEM
$507M
| $3.45M | ﹤0.01% |
180,038
-5,859
| -3% | -$111K |
2023 Q3
3 quarters
|
|
3206
Thryv Holdings
THRY
$67.5M
| $3.44M | ﹤0.01% |
193,268
-180,841
| -48% | -$3.84M |
2021 Q2
12 quarters
|
|
3207
Cognyte Software
CGNT
$645M
| $3.44M | ﹤0.01% |
450,616
-172,010
| -28% | -$1.29M |
2021 Q1
13 quarters
|
|
3208
Dyne Therapeutics
DYN
$2.84B
| $3.44M | ﹤0.01% |
97,514
+43,144
| +79% | +$1.25M |
2020 Q4
14 quarters
|
|
|
BSCO
3209
DELISTED
Invesco BulletShares 2024 Corporate Bond ETF
BSCO
| $3.44M | ﹤0.01% |
163,285
+58,475
| +56% | +$1.23M |
2019 Q3
19 quarters
|
|
3210
PUT
Cleveland-Cliffs
CLF
$6.46B
| $3.44M | ﹤0.01% |
223,300
| – | – |
2022 Q4
6 quarters
|
|
3211
State Street SPDR Dow Jones REIT ETF
RWR
$1.77B
| $3.43M | ﹤0.01% |
36,848
-2,509
| -6% | -$228K |
2013 Q2
44 quarters
|
|
3212
Worthington Enterprises
WOR
$2.97B
| $3.43M | ﹤0.01% |
72,430
-32,807
| -31% | -$1.85M |
2013 Q2
44 quarters
|
|
3213
CALL
Quest Diagnostics
DGX
$25.8B
| $3.42M | ﹤0.01% |
+25,000
| New | +$3.42M |
2024 Q2
0 quarters
|
|
|
3214
PUT
Quest Diagnostics
DGX
$25.8B
| $3.42M | ﹤0.01% |
+25,000
| New | +$3.42M |
2024 Q2
0 quarters
|
|
3215
Under Armour Class C
UA
$1.97B
| $3.42M | ﹤0.01% |
523,099
+24,018
| +5% | +$159K |
2016 Q2
32 quarters
|
|
3216
NCR Atleos
NATL
$3.36B
| $3.42M | ﹤0.01% |
126,406
-66,915
| -35% | -$1.63M |
2023 Q4
2 quarters
|
|
3217
OraSure Technologies
OSUR
$273M
| $3.42M | ﹤0.01% |
801,717
+525,737
| +190% | +$2.67M |
2015 Q4
34 quarters
|
|
3218
Global Net Lease
GNL
$1.91B
| $3.41M | ﹤0.01% |
464,425
-241,535
| -34% | -$1.75M |
2016 Q4
30 quarters
|
|
3219
IAMGOLD
IAG
$10.6B
| $3.4M | ﹤0.01% |
907,069
+493,893
| +120% | +$1.88M |
2021 Q4
10 quarters
|
|
|
RWT
3220
Redwood Trust
RWT
$443M
| $3.4M | ﹤0.01% |
524,083
-108,129
| -17% | -$672K |
2013 Q2
44 quarters
|
|
3221
Cytek Biosciences
CTKB
$763M
| $3.4M | ﹤0.01% |
608,440
+523,028
| +612% | +$3.14M |
2021 Q3
11 quarters
|
|
3222
Tandem Diabetes Care
TNDM
$1.15B
| $3.39M | ﹤0.01% |
84,228
-9,434
| -10% | -$394K |
2018 Q1
25 quarters
|
|
3223
Sprout Social
SPT
$611M
| $3.39M | ﹤0.01% |
95,041
-785
| -0.8% | -$31.6K |
2020 Q1
17 quarters
|
|
3224
Kimco Realty Corp 7.25% Class N Preferred Stock
KIM.PRN
$82.8M
| $3.38M | ﹤0.01% |
62,000
| – | – |
2024 Q1
1 quarter
|
|
3225
Mach Natural Resources
MNR
$1.72B
| $3.38M | ﹤0.01% |
177,558
+169,742
| +2,172% | +$3.36M |
2023 Q4
2 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2024 Portfolio in Review
As of Q2 2024, JP Morgan Chase held 7,917 positions worth $1.22T, up 3% from $1.18T the previous quarter. Its ten largest holdings account for 24% of the portfolio.
JP Morgan Chase's Q2 2024 filing shows 549 new, 2,506 increased, 3,286 reduced and 578 closed positions. Its largest new stake was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M. The largest sale was JP Morgan Alerian MLP Index ETN 5/24/24, an estimated $2.4B.
By sector, the portfolio is most concentrated in Miscellaneous at 24% of assets, down from 25% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2024 buy was BlackRock Flexible Income ETF: 6,829,171 shares worth $357M.
- JP Morgan Chase added most to Apple in Q2 2024, an estimated $4.65B increase.
- JP Morgan Chase's biggest Q2 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $2.11B.
- JP Morgan Chase fully exited JP Morgan Alerian MLP Index ETN 5/24/24 in Q2 2024, selling an estimated $2.4B.
- JP Morgan Chase's ten largest holdings make up 24% of its $1.22T portfolio in Q2 2024.
- JP Morgan Chase opened 549 new positions and closed 578 in Q2 2024.
- JP Morgan Chase's portfolio value rose 3% quarter-over-quarter to $1.22T.
Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.